3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
44
OTHER
24
NIH
2
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Lymphoid
3
Gastrointestinal
2
Dermatologic
2
Tumor-Agnostic
1
Plasma cell
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Conditions
Advanced Solid Tumors
1
Interventions
Cisplatin
6
Pemetrexed
5
Carboplatin
4
Standard of Care
3
Specimen Handling
3
Practice Guidelines as Topic
3
Interviews as Topic
3
Immunoenzyme Techniques
3
Docetaxel
3
raltitrexed
2
Vincristine
2
Trabectedin
2
N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide
2
Irinotecan
2
Immunohistochemistry
2
Gemcitabine
2
Etoposide
2
Early Intervention, Educational
2
Bortezomib
2
AEG 35156
2
temsirolimus
1
sabarubicin
1
pembrolizumab
1
nintedanib
1
halofuginone
1
ascrinvacumab
1
Triptorelin Pamoate
1
Thrombopoietin
1
Theophylline
1
SB939 compound
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Nivolumab
×
Other solid neoplasm
×
Clear all
NCT03461952
2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2
Terminated
4 enrolled
4 charts